Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 62, Issue 3, 2010, Pages 837-844

  Kao, Amy H ^a   Navratil, Jeannine S ^a   Ruffing, Margie J ^a   Liu, Chau Ching ^a   Hawkins, Douglas ^b   McKinnon, Kathleen M ^a   Danchenko, Natalya ^c   Ahearn, Joseph M ^a   Manzi, Susan ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; DOUBLE STRANDED DNA; ESTROGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; COMPLEMENT C3D; COMPLEMENT C4B; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX;

EID: 77649094042     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27267     Document Type: Article

References (24)

1. Illei G, Lipsky P. Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 2004;6:382-90.
2. Illei G, Tackey E, Lapteva L, Lipsky P. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 2004;50:2048-65.
3. Liang M, Socher S, Larson M, Schur P. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
4. Buyon J, Petri M, Kim M, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
5. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg D. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003;42:1372-9.
6. Schur P, Sandson J. Immunological factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533-8.
7. Walport M. Complement and systemic lupus erythematosus. Arthritis Res 2002;4 Suppl 3:S279-93.
8. Lloyd W, Schur P. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981;60:208-17.
9. Hopkins P, Belmont H, Buyon J, Philips M, Weissmann G, Abramson S. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988;31: 632-41.
10. Sturfelt G, Jonasson L, Sjoholm A. Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol 1985;14:184-96.
11. Buyon J, Tamerius J, Belmont H, Abramson S. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
12. Falk R, Agustin M, Dalmasso P, Kim Y, Lam S, Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 1985;312:1594-9.
13. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996;39:1178-88.
14. Mollnes TE, Haga HJ, Brun JG, Nielsen EW, Sjoholm A, Sturfeldt G, et al. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology (Oxford) 1999;38: 933-40.
15. Abrass C, Nies K, Louie J, Border W, Glassock R. Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1980;23:273-82.
16. Esdaile J, Joseph L, Abrahamowicz M, Danoff D, Clarke A. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996;23:1891-6.
17. Esdaile J, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996;39:370-8.
18. Liu CC, Ahearn J, Manzi S. Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future. Curr Rheumatol Rep 2004;6:85-8.
19. Manzi S, Navartil JS, Ruffing MJ, Liu CC, Danchenko N, Nilson SE, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004;50:3596-604.
20. Liu CC, Manzi S, Kao AH, Navartil JS, Ruffing MJ, Ahearn JM. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. Arthritis Rheum 2005;52:3087-99.
21. Tieley C, Romans D, Crookston M. Localization of Chido and Rodgers determinants to the C4d fragment of human C4. Nature 1978;276:713-5.
22. Atkinson JP, Chan AC, Karp DR, Killion CC, Brown R, Spinella D, et al. Origin of the fourth component of complement related Chido and Rodgers blood group antigens. Complement 1988;5: 65-76.
23. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
24. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.